CUE BIOPHARMA

NASDAQ: CUE (Cue Biopharma, Inc.)

Kemas kini terakhir: 2 jam lalu

7.87

-6.23 (-44.18%)

Penutupan Terdahulu 14.10
Jumlah Dagangan 559,118
Harga / Jualan (P/S) 1.94
Harga / Buku (P/B) 36.54
Julat 52 Minggu
4.98 (-36%) — 45.50 (478%)
Margin Operasi (TTM) -2,921.38%
EPS Cair (TTM) -0.640
Pertumbuhan Hasil Suku Tahunan (YOY) -75.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 108.28%
Nisbah Semasa (MRQ) 1.03
Aliran Tunai Operasi (OCF TTM) -34.72 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -18.34 M
Pulangan Atas Aset (ROA TTM) -67.62%
Pulangan Atas Ekuiti (ROE TTM) -221.66%

AISkor Stockmoo

-2.4
Nilai 30% -4.2
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Keuntungan lemah. Kecairan jangka pendek nipis. Aliran tunai negatif. info
Pulangan di bawah kos modalnya. Pulangan atas modal menurun. info
Masa 30% -3.6
Daripada analisis teknikal AI kami terhadap carta. info NA
Tiada aliran jelas sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Corak Lilin info NA
Aliran bagi Tempoh Pegangan Anda info NA
Sentimen 20% 0.0
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Berita info NA
Wang Pintar 20% 1.9
Aktiviti Orang Dalam info NA
Institusi bersih +75.12% daripada saham dalam pemfailan 13F terkini: 35 pemegang menambah, 19 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +171.0% dari 31 Aug hingga 30 Oct 2026, 7.6 hari untuk tutup (FINRA). info
Keadaan pasaran dan sektor lemah.
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Tidak dikira dalam skor
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Aliran turun bagi ketiga-tiga tempoh. Momentum jangka pendek menurun. info
Tiada isyarat jelas daripada sokongan dan rintangan. info
Skor Akhir -2.43

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menaik
Biotechnology (Global) Bercampur Menaik
Stok Cue Biopharma, Inc. Bercampur Bercampur

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
CUE - - - 36.54
TRML 1 B - - 4.76
CTMX - - - 1.55
HURA - - - 4.84
GANX - - - 4.54
PRTA - - - 1.56

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Core
% Dimiliki oleh Orang Dalam 0.35%
% Dimiliki oleh Institusi 19.45%

Pemilikan

Nama Tarikh Syer Dipegang
Tetragon Partners Gp Ltd 30 Jun 2026 93,819

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 65.83%

Kedudukan Pemegang Saham
Bertambah 35 3,280,294
Berkurang 19 254,853
Baharu 17 2,454,175
Dijual habis 8 221,057

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 862,798 7.6
15 Oct 2026 792,553 3.7
30 Sep 2026 702,198 1.1
15 Sep 2026 332,105 2.4
31 Aug 2026 318,420 1.8
14 Aug 2026 327,442 1.6

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

1 Positif 0 Negatif 0 Neutral
Tarikh Jenis Butiran
16 Nov 2026 Yahoo Finance Cue Biopharma Reports Third Quarter 2026 Financial Results and Recent Business Highlights
CUE-221 Phase 2 chronic spontaneous urticaria (CSU) findings highlight differentiated clinical benefit and potential to expand the addressable patient population in CSU and food allergy CUE-401 enters clinical development with initiation of first-in-human dosing, achieving key 2026 milestone…
28 Sep 2026 Yahoo Finance Cue Biopharma’s CUE-221 Hits Phase II Goals, Shows Durable CSU Response
Cue Biopharma (NASDAQ:CUE) reported positive top-line results from a Phase II trial of CUE-221 in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, whose disease was inadequately controlled with H1 antihistamines. The randomized, double-blind, placebo-controlled study evaluate…
25 Sep 2026 Yahoo Finance Cue Biopharma (CUE) Reports Hives Drug Results. Can Longer Relief Set it Apart?
Cue Biopharma, Inc. (NASDAQ:CUE) reported positive Phase 2 results for CUE-221 on September 20. The randomized, double-blind study enrolled 145 patients in China with moderate to severe chronic spontaneous urticaria, or chronic hives, inadequately controlled by H1 antihistamines. At week 12…
22 Sep 2026 Yahoo Finance An orexin drug’s ‘proof-of-concept’ in ADHD; Cue’s ‘unwarranted’ share slide
Alkermes’ results heightened anticipation for a coming readout in 2027. Elsewhere, AbbVie leaned into AI drug discovery and the FDA expanded use of Eli Lilly’s breast cancer pill.
21 Sep 2026 Yahoo Finance Cue Biopharma Shares Jump 41.6% Premarket Following Phase 2 Trial Results
Cue Biopharma (NASDAQ:CUE) shares rose 41. 6% in premarket trading after the company reported positive topline results from a Phase 2 clinical trial evaluating CUE-221 in patients with moderate to severe chronic spontaneous urticaria.
20 Sep 2026 Yahoo Finance Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria
Results support potential for differentiated clinical impact for patients suffering from chronic hives and advancement to Phase 2b/3 registration enabling studyPrimary endpoint and the key secondary endpoint were met with high statistical significance and CUE-221 demonstrated an overall favorable…

Isyarat Terkini corak lilin dan silang EMA

▼ Silang maut 8 sesi lalu · 04 Nov
Jangka panjang · EMA 50/200
EMA 50 hari melintas ke bawah EMA 200 hari, tanda yang diperhatikan ramai bahawa arah aliran jangka panjang telah berubah menurun.

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda